Valsartan improves the lower limit of cerebral autoregulation in rats

Hypertension Research

Volumn 29, Issue 8, 2006, Pages 621-626

  Takada, Junichi ^a   Ibayashi, Setsuro ^a   Ooboshi, Hiroaki ^a   Ago, Tetsuro ^a   Ishikawa, Eiichi ^a   Kamouchi, Masahiro ^a   Kitazono, Takanari ^a   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiotensin; Autoregulation; Cerebral blood flow; Receptor; Valsartan

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; VALSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN CIRCULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; ENDOTHELIUM CELL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LASER DOPPLER FLOWMETRY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BASILAR ARTERY; CEREBRAL ARTERIES; ENDOTHELIUM, VASCULAR; HOMEOSTASIS; MALE; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, INBRED SHR; RECEPTORS, ANGIOTENSIN; REGIONAL BLOOD FLOW; TELENCEPHALON; TETRAZOLES; VALINE;

EID: 33748950839     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.621     Document Type: Article

References (30)

1. Suzuki H, Kanno Y: Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307-314.
2. Iino Y, Hayashi M, Kawamura T, et al: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21-30.
3. Nakamura T, Kanno Y, Takenaka T, Suzuki H: An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res 2005; 28: 415-423.
4. Takeuchi K, Ideishi M, Tashiro T, et al: Higher small arterial elasticity in hypertensive patients treated with angiotensin II receptor blockers. Hypertens Res 2005; 28: 639-644.
5. Barry DI, Paulson OB, Jarden JO, Juhler M, Graham DI, Strandgaard S: Effects of captopril on cerebral blood flow in normotensive and hypertensive rats. Am J Med 1984; 76: 79-85.
6. Bray L, Lartaud I, Muller F, Atkinson J, Capdeville C: Effects of the angiotensin I converting enzyme inhibitor perindopril on cerebral blood flow in awake hypertensive rats. Am J Hypertens 1991; 4: 246S-252S.
7. Cai H, Yao H, Ibayashi S, et al: Effects of long-acting angiotensin-converting enzyme inhibitor, imidapril, on the lower limit of cerebral blood flow autoregulation in hypertensive rats. Eur J Pharmacol 1998; 341: 73-77.
8. Lartaud I, Makki T, Bray-des-Boscs L, et al: Effect of chronic ANG I-converting enzyme inhibition on aging processes. IV. Cerebral blood flow regulation. Am J Physiol 1994; 267: R687-R694.
9. Muller F, Lartaud I, Bray L, et al: Chronic treatment with the angiotensin I converting enzyme inhibitor, perindopril, restores the lower limit of autoregulation of cerebral blood flow in the awake renovascular hypertensive rat. J Hypertens 1990; 8: 1037-1042.
10. Torup M, Waldemar G, Paulson OB: Ceranapril and cerebral blood flow autoregulation. J Hypertens 1993; 11: 399-405.
11. Naveri L, Stromberg C, Saavedra JM: Angiotensin II AT2 receptor stimulation extends the upper limit of cerebral blood flow autoregulation: agonist effects of CGP 42112 and PD 123319. J Cereb Blood Flow Metab 1994; 14: 38-44.
12. Vraamark T, Waldemar G, Strandgaard S, Paulson OB: Angiotensin II receptor antagonist CV- 11974 and cerebral blood flow autoregulation. J Hypertens 1995; 13: 755-761.
13. Oku N, Kitagawa K, Imaizumi M, et al: Hemodynamic influences of losartan on the brain in hypertensive patients. Hypertens Res 2005; 28: 43-49.
14. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993; 110: 761-771.
15. de Gasparo M, Whitebread S: Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept 1995; 59: 303-311.
16. 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31: 2478-2486.
17. Tsutsumi K, Saavedra JM: Characterization of AT2 angiotensin II receptors in rat anterior cerebral arteries. Am J Physiol 1991; 261: H667-H670.
18. Toyoda K, Fujii K, Ibayashi S, Nagao T, Kitazono T, Fujishima M: Role of nitric oxide in regulation of brain stem circulation during hypotension. J Cereb Blood Flow Metab 1997; 17: 1089-1096.
19. Zaharchuk G, Mandeville JB, Bogdanov AA Jr, Weissleder R, Rosen BR, Marota JJ: Cerebrovascular dynamics of autoregulation and hypoperfusion. An MRI study of CBF and changes in total and microvascular cerebral blood volume during hemorrhagic hypotension. Stroke 1999; 30: 2197-2204.
20. Verhaegen MJ, Todd MM, Hindman BJ, Warner DS: Cerebral autoregulation during moderate hypothermia in rats. Stroke 1993; 24: 407-414.
21. Takada J, Ibayashi S, Nagao T, Ooboshi H, Kitazono T, Fujishima M: Bradykinin mediates the acute effect of an angiotensin-converting enzyme inhibitor on cerebral autoregulation in rats. Stroke 2001; 32: 1216-1219.
22. Kitayama J, Kitazono T, Ibayashi S, et al: Role of phosphatidylinositol 3-kinase in acetylcholine-induced dilatation of rat basilar artery. Stroke 2000; 31: 2487-2493.
23. Ago T, Kitazono T, Ooboshi H, et al: Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004; 109: 227-233.
24. Kramer C, Sunkomat J, Witte J, et al: Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770-776.
25. Campbell DJ: Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE. Clin Exp Pharmacol Physiol 1995; 22: 903-911.
26. Kitazono T, Ibayashi S, Nagao T, Fujii K, Kagiyama T, Fujishima M: Role of tyrosine kinase in dilator responses of rat basilar artery in vivo. Hypertension 1998; 31: 861-865.
27. 2 receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol 2002; 136: 484-491.
28. Sosa-Canache B, Cierco M, Gutierrez CI, Israel A: Role of bradykinins and nitric oxide in the AT2 receptor-mediated hypotension. J Hum Hypertens 2000; 14 (Suppl 1): S40-S46.
29. Tsutsumi Y, Matsubara H, Masaki H, et al: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935.
30. 2+ channel antagonist, modifies cerebral blood flow autoregulation in hypertensive rats. Eur J Pharmacol 1996; 313: 103-106.